TSLA
Tesla
-- 436.180 MU
Micron Technology
-- 86.490 NVDA
NVIDIA
-- 131.930 QUBT
Quantum Computing
-- 17.300 NUKK
Nukkleus
-- 49.020 
Update
$Annexon (ANNX.US)$ Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
4 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE
Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS
ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS)
Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across Multiple Measurements
Conference Call and Webcast Today at 8:30 a.m. ET
4 MINUTES AGO, 7:30 AM EST
VIA GLOBENEWSWIRE
Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS
ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS)
Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across Multiple Measurements
Conference Call and Webcast Today at 8:30 a.m. ET
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Jaguar8 : I super like esp GBS is as ascending paralysis so debilitating
Trytosaveabit OP Jaguar8 : 100%